This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Treatment of Legionnaire's disease

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • Erythromycin is the treatment of choice
  • If this cannot be tolerated, azithromycin, clarithromycin, levofloxacin, ciprofloxacin and doxycycline can all be used. (1) In some cases, tetracycline, ciprofloxacin, and other fluoroquinolone and macrolide drugs may be considered. (2)
  • Any course of treatment should be for 10-21 days and is usually intravenous, at least at first. (3)
  • In critically ill patients macrolides and fluoroquinolones should be used as first-line therapy.
  • Severe infections may require the addition of rifampicin
  • Support must be given in the event of any system failure - ventilation in respiratory failure, dialysis in renal failure

References:

  1. File TM Jr, Garau J, Blasi F, et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest. 2004 May;125(5):1888-901.
  2. Mills GD. et al. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ. 2005 Feb
  3. Amsden GW. Treatment of Legionnaires' disease. Drugs. 2005;65(5):605-14.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.